In summary, we found that targeting BRD4 can sensitize NSCLC cells to TRAIL induced cell proliferation inhibition and apoptosis induction, which occur partly through the inactivation of the NF-κB pathway. Here, NFKB1 is linked to non-small cell lung carcinoma.